Biogen Inc. $BIIB Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its position in shares of Biogen Inc. (NASDAQ:BIIB) by 12.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,079,119 shares of the biotechnology company’s stock after acquiring an additional 118,474 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Biogen were worth $197,881,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of BIIB. Parallel Advisors LLC lifted its position in Biogen by 1.5% in the first quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock valued at $801,000 after buying an additional 65 shares during the last quarter. AlphaCentric Advisors LLC raised its stake in shares of Biogen by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 3,835 shares of the biotechnology company’s stock valued at $703,000 after acquiring an additional 208 shares in the last quarter. KBC Group NV raised its stake in shares of Biogen by 339.5% in the first quarter. KBC Group NV now owns 234,692 shares of the biotechnology company’s stock valued at $43,026,000 after acquiring an additional 181,294 shares in the last quarter. SEB Asset Management AB purchased a new position in Biogen in the first quarter valued at $7,676,000. Finally, Swiss National Bank grew its stake in Biogen by 7.2% during the 1st quarter. Swiss National Bank now owns 430,600 shares of the biotechnology company’s stock worth $78,942,000 after purchasing an additional 28,800 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on BIIB shares. Wedbush reissued a “neutral” rating and set a $201.00 price objective on shares of Biogen in a research report on Monday, July 13th. Wall Street Zen raised shares of Biogen from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. The Goldman Sachs Group lifted their price target on Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Needham & Company LLC boosted their price objective on Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Argus raised Biogen to a “hold” rating in a report on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $220.57.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $202.19 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The firm has a market capitalization of $29.85 billion, a price-to-earnings ratio of 21.69 and a beta of 0.16. Biogen Inc. has a 12 month low of $124.56 and a 12 month high of $219.72. The business’s 50 day simple moving average is $199.78 and its 200-day simple moving average is $189.85.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The business had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. During the same period in the previous year, the firm posted $3.02 earnings per share. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities analysts forecast that Biogen Inc. will post 11.37 earnings per share for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.